GlassScriptPhysician profile
Kelly Roberts
NPI 1699382465
$3,954.64
in general payments reported to CMS, 2019-2025
30 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $813 · 2022: $479 · 2023: $277 · 2024: $863 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,663.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,161.54 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $776.45 | 2021-2025 | Wegovy, Ozempic |
| Tandem Diabetes Care, INC. | $255.73 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $244.37 | 2021-2025 | Freestyle Libre 3 |
| Averitas Pharma INC. | $139.99 | 2025 | Qutenza |
| Insulet Corporation | $131.22 | 2024-2025 | Omnipod |
| Beta Bionics, INC. | $131.20 | 2024 | Ilet Bionic Pancreas |
| Astellas Pharma US INC | $123.55 | 2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $95.05 | 2022 | |
| Amgen INC. | $87.43 | 2025 | Tepezza, Evenity, Repatha |
| Lilly USA, LLC | $83.37 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Xeris Pharmaceuticals, INC. | $70.47 | 2022 | |
| Ucb, INC. | $68.87 | 2021 | |
| Ascensia Diabetes Care US INC. | $67.14 | 2021 | |
| Kyowa Kirin, INC. | $55.86 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $55.25 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.49 | 2025 | Jardiance |
| Soleno Therapeutics, INC. | $48.17 | 2025 | Vykat Xr |
| Abbvie INC. | $46.88 | 2025 | |
| Sanofi-Aventis U.S. LLC | $43.69 | 2021-2024 | |
| Madrigal Pharmaceuticals | $41.79 | 2025 | Rezdiffra |
| Ionis Pharmaceuticals, INC. | $29.29 | 2025 | Tryngolza |
| Recordati_rare_diseases_inc. | $24.40 | 2025 | Isturisa |
| Alexion Pharmaceuticals, INC. | $21.91 | 2025 | Strensiq |
| Antares Pharma, INC. | $21.00 | 2025 | Xyosted |
| Biohaven Pharmaceuticals, INC. | $16.78 | 2021 | |
| Corcept Therapeutics | $16.08 | 2025 | Korlym |
| Ibsa Pharma INC. | $15.37 | 2025 | Tirosint, Flector, Licart |
| Almatica Pharma LLC | $15.10 | 2025 | Teriparatide |
| Mannkind Corporation | $14.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.